As revealed by in vivo bioluminescence imaging and resected ovaries, αPD‐1 or CTS/p(I:C)‐MMA monotherapy showed mild to moderate effects on reducing the tumor burden, and the combination therapy eliminated the cancer cells from the ovaries (Figure 5e,f and Figure S24, Supporting Information). The gene discussed is TTR; the disease is neoplasm.